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According to a report published by the World Health Organization
in 2003, medication compliance among patients suffering from
chronic diseases averages only 50% in developed countries [1].
Poor compliance can lead to reduced drug effectiveness,
increased morbidity, and increased health care expenditures.
Medication compliance (synonym: adherence) refers to the act
of conforming to the recommendations made by the provider
with respect to the timing, dosage, and frequency of medication
taking [2]. Therefore, medication compliance may be deﬁned as
“the extent to which a patient acts in accordance with the
prescribed interval and dose of a dosing regimen” [2]. Compliance
is measured over a period of time and reported as a percentage.
Medication persistence, on the other hand, may be deﬁned as
“the duration of time from initiation to discontinuation of ther-
apy” [2]. Although ideally, the rate of compliance with the dosing
regimen and persistence with therapy are incorporated in the
treatment incremental cost-effectiveness ratio (ICER), the non-
acceptance of the drug treatment and regimen following the
initial consultation is usually taken into account in a model’s “no
treatment” arm [3] and thus is not reﬂected in the treatment
ICER. The nonacceptance of the drug treatment and regimen,
however, is relevant to the determination of the ICER of
adherence-improving measures because adherence-improving
measures reduce nonacceptance.
Recently, a theoretical model was published that calculates
the ICER of programs to improve patient adherence [4]. The
purpose of this note was to apply this model to test the internal
validity of published models on the cost-effectiveness of adher-
ence improvement.
Cost-effectiveness models should be validated both internally
and externally, as recommended by the Good Research Practicesin Modeling Task Force [5]. In external validation, a model is used
to simulate a real scenario, such as a clinical trial, and the
predicted outcomes are compared with the real-world ones [5].
Internal validation (synonym: veriﬁcation) examines the extent
to which the mathematical calculations are performed correctly
and are consistent with the model’s speciﬁcations [5].Methods
The ICER of programs to improve patient adherence is calculated
as follows [4]:
ICER¼ Δcim,ptð1-coptÞ  Δcopt  Δbt
þ Δct
Δbt
ð1Þ
where
Δcim,pt is the per-patient implementation cost of improving
patient compliance,
copt is the baseline compliance rate of patients (acceptance rate
of starting drug treatment and regimen without implementation),
Δcopt is the change in the rate of noncompliance of patients,
Δct is the net cost of care per additional patient treated, and
Δbt is the health gain per additional patient treated.
Without the patient adherence program, the ﬁrst term of the
equation drops out and we obtain the treatment ICER, calculated
as Δct/Δbt. The ﬁrst term considers that health beneﬁts of the
adherence program accrue only in those who are compliant. Costs
of the adherence program, however, incur for all participants.
Note that double counting of costs both in the implementa-
tion cost term and in the treatment cost term should be avoided.
The model shows that Δcim,pt and Δcopt are in a ﬁxed ratio.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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variables in proportion.Application Examples
Recently, Ito et al. [6] presented a decision model that simulates
costs and effects of interventions to improve medication adher-
ence after myocardial infarction over lifetime. The adherence
deﬁnition by the authors, which refers to “full adherence” and
not to partial adherence or persistence, is consistent with copt in
Equation 1. To test for internal validity, we checked the results of
the multiway sensitivity analyses presented in Figures 2 and 3.
The ﬁgures show for which combinations of relative increase in
full adherence and cost of an adherence-improving measure the
preference for an adherence-improving measure does not change,
that is, the ICER stays the same. On the basis of the above model
[4], we would have expected that to offset an increase in the cost
of an adherence-improving measure, the effectiveness of that
measure (or relative improvement in adherence) needs to increase
exactly in proportion. In Figure 2, however, increasing the cost of
disease management from $250 to more than $500 requires less
than doubling of relative adherence (an increase from 16% to 25%)
to yield the same ICER. Similarly, in Figure 3, the relationship
between changes in Δcim,pt and Δcopt is not ﬁxed. Apparently, the
analysis is therefore not internally valid.
Another model, presented by Ladabaum and Phillips [7],
assessed the cost-effectiveness of increasing the uptake (accept-
ance) of colorectal cancer screening. In a threshold analysis on
increasing screening adherence from 40% (baseline) to 75%, the
authors estimated that an adherence program could cost as
much as $1975 over lifetime to remain cost-effective at $50,000
per life-year gained. When plugging this cost estimate as well as
data from Table 2 into Equation 1, however, we obtain an ICER of
$113,204 per life-year gained (¼ 1975/(0.35  (18.744  18.686)) þ
(2736  1813)/(18.744  18.686)). Hence, at a program cost of $1975
over lifetime, the uptake of colorectal cancer screening is not
cost-effective at $50,000 per life-year gained.Discussion
This note shows that decision models that calculate the ICER of
improving patient adherence can be tested for internal validity byusing Equation 1. When this test fails, the program code of the
decision model needs to be examined for syntactical errors. Yet,
it is also important to point out that even if Equation 1 applies,
one cannot rule out a modeling error and thus needs to apply
internal validation tests suggested by the Good Research Practi-
ces in Modeling Task Force [5] or presented elsewhere [8,9]. For
example, it could be the case that while costs and effects of
adherence improvement are appropriately considered, costs
and effects of treatment are not modeled appropriately
because of a modeling error. The suggested test then provides
modelers with additional certainty that the model is internally
valid but does not provide the ultimate proof of internal
validity.
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